IPO registrations (S-1, F-1) · Registrants
Trevi Therapeutics, Inc.
- SEC CIK
- 1563880 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-04-05, last 2021-08-27; 3 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2019-05-08; declared effective 2019-05-07; withdrawal requested 2021-10-08
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 195 CHURCH STREET, 16TH FLOOR, New Haven, CT 06510
- EIN
- 45-0834299
- Ticker
- TRVI (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Trevi Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2019-05-08, an initial public offering)
- Shares sold
- 5,500,000
- Gross proceeds
- $55,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol TRVI
- Lead underwriters
- Leerink Partners; Stifel; BMO Capital Markets
- Syndicate
- Needham & Company
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: TREVI THERAPEUTICS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: TREVI THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Form D issuer: Trevi Therapeutics, Inc. EXACT (CIK (EXACT))
- SEC filer: Trevi Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Peter F Drake Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-04-05 | S-1 | S-1 (registration) | Trevi Therapeutics, Inc. | 0001193125-19-099340 ↗ |
| 2019-04-22 | S-1/A | S-1/A (amendment) | Trevi Therapeutics, Inc. | 0001193125-19-112820 ↗ |
| 2019-05-06 | S-1/A | S-1/A (amendment) | Trevi Therapeutics, Inc. | 0001193125-19-138079 ↗ |
| 2019-05-07 | S-1/A | S-1/A (amendment) | Trevi Therapeutics, Inc. | 0001193125-19-138831 ↗ |
| 2019-05-07 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-19-001033 ↗ |
| 2019-05-08 | 424B4 | 424B4 (final prospectus) | Trevi Therapeutics, Inc. | 0001193125-19-141374 ↗ |
| 2020-07-02 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-20-001643 ↗ |
| 2021-07-07 | S-1 | S-1 (registration) | Trevi Therapeutics, Inc. | 0001193125-21-209928 ↗ |
| 2021-07-14 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-21-002767 ↗ |
| 2021-08-27 | S-1 | S-1 (registration) | Trevi Therapeutics, Inc. | 0001193125-21-259333 ↗ |
| 2021-10-08 | RW | RW (withdrawal request) | Trevi Therapeutics, Inc. | 0001193125-21-295518 ↗ |
| 2021-10-25 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-21-004024 ↗ |
| 2021-11-16 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-21-004369 ↗ |
| 2022-05-11 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-22-001421 ↗ |
| 2023-08-15 | EFFECT | EFFECT (declared effective) | Trevi Therapeutics, Inc. | 9999999995-23-002394 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-05-07 | S-1/A | registration statement | $10.00 | 5,500,000 | $55,000,000 | Nasdaq TRVI | 4 | primary document; price sentence, shares headline, proceeds computed, cover names 4 | document ↗ | |
| 2019-05-08 | 424B4 | final prospectus | $10.00 | 5,500,000 | $55,000,000 | Nasdaq TRVI | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Agger Mette Kirstine | Director | 3 | 2019 | ||
| Aperture Venture Partners IV, L.P. | TenPercentOwner | 2 | 2019 | ||
| Aperture Ventures IV Management, LLC | TenPercentOwner | 2 | 2019 | ||
| BARRIS PETER J | TenPercentOwner | 2 | 2019 | ||
| BASKETT FOREST | TenPercentOwner | 6 | 2019–2026 | ||
| Behbahani Ali | TenPercentOwner | 6 | 2019–2026 | ||
| BONDERMAN DAVID | Other; TenPercentOwner | 8 | 2019–2022 | ||
| Brett-Smith Helena | Officer | Chief Development Officer | 2 | 2019–2020 | |
| Chang Carmen | TenPercentOwner | 6 | 2019–2026 | ||
| COULTER JAMES G | Other; TenPercentOwner | 8 | 2019–2022 | ||
| Drake Debra A | TenPercentOwner | 2 | 2019 | ||
| DRAKE PETER F | TenPercentOwner | 2 | 2019 | person page Fuzzy | |
| Florence Anthony A. Jr. | TenPercentOwner | 6 | 2019–2026 | ||
| GOOD JENNIFER L | Director,Officer; Director,Officer,TenPercentOwner | President and CEO; President & CEO; See Remarks | 20 | 2019–2026 | |
| Heffernan Michael Thomas | Director | 12 | 2019–2026 | ||
| Lundbeckfond Invest A/S | TenPercentOwner | 2 | 2019 | ||
| Makhzoumi Mohamad | TenPercentOwner | 6 | 2019–2026 | ||
| MAKOWER JOSHUA | TenPercentOwner | 3 | 2019–2020 | ||
| Mathers Edward T | Director | 10 | 2019–2026 | ||
| Mazabraud Yann | Officer | See Remarks | 3 | 2019–2020 | |
| Meeker David P | Director; Director,TenPercentOwner | 12 | 2019–2026 | ||
| Mellon Family Investment Co V | TenPercentOwner | 2 | 2019 | ||
| MFIC V, LLC | TenPercentOwner | 2 | 2019 | ||
| Mitsak Anna Guyer | Director | 3 | 2019 | ||
| MOTT DAVID M | TenPercentOwner | 2 | 2019 | ||
| Muscolo Frank P | Officer | Controller | 4 | 2019–2021 | |
| Nadav Eran | Director | 2 | 2019 | ||
| NEA 16 GP, LLC | TenPercentOwner | 6 | 2019–2026 | ||
| NEA Partners 16, L.P. | TenPercentOwner | 6 | 2019–2026 | ||
| New Enterprise Associates 16, L.P. | TenPercentOwner | 6 | 2019–2026 | ||
| Omega Fund V GP, L.P. | TenPercentOwner | 2 | 2019 | ||
| Omega Fund V GP Manager, Ltd. | TenPercentOwner | 2 | 2019 | ||
| Omega Fund V, L.P. | TenPercentOwner | 2 | 2019 | ||
| O'Shea William J | TenPercentOwner | 1 | 2019 | ||
| Richard King Mellon Foundation | TenPercentOwner | 2 | 2019 | ||
| SANDELL SCOTT D | TenPercentOwner | 6 | 2019–2026 | ||
| SCIASCIA THOMAS | Officer; Officer,TenPercentOwner | Chief Medical Officer; Chief Scientific Officer | 19 | 2019–2026 | |
| Seiter Christopher | Officer | CFO; Chief Financial Officer | 4 | 2019–2021 | |
| Sonsini Peter W. | TenPercentOwner | 5 | 2019–2022 | ||
| TPG Group Holdings (SBS) Advisors, Inc. | TenPercentOwner | 4 | 2019–2020 | ||
| VANLENT ANNE | Director | 11 | 2019–2026 | ||
| Walker Paul Edward | Director; TenPercentOwner | 6 | 2019–2026 | ||
| OSHEA WILLIAM J | TenPercentOwner | 2 | 2019 | ||
| Cassella James V | Director; Officer | Chief Development Officer | 10 | 2020–2026 | |
| Colangelo Dominick | Director | 9 | 2020–2026 | ||
| Forbes William P | Officer | Chief Development Officer | 5 | 2021–2022 | |
| Galletta Christopher | Officer | See Remarks | 11 | 2021–2026 | |
| Delfini Lisa | Officer | Chief Financial Officer | 19 | 2021–2025 | |
| TPG GP A, LLC | Other; TenPercentOwner | 5 | 2022 | ||
| WINKELRIED JON | Other; TenPercentOwner | 5 | 2022 | ||
| Clark David J | Officer | Chief Medical Officer | 3 | 2022–2024 | |
| Simon Farrell | Officer | Chief Commercial Officer | 9 | 2023–2026 | |
| HASTINGS DAVID C | Officer | Chief Financial Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-04-18 | Trevi Therapeutics, Inc. | Biotechnology | $54,999,998 | $54,999,998 | 12 | 1 |
| 2021-10-21 | Trevi Therapeutics, Inc. | Biotechnology | $3,000,000 | $3,000,000 | 1 | 1 |
| 2021-10-20 | Trevi Therapeutics, Inc. | Biotechnology | $11,819,891 | $11,819,891 | 1 | 1 |
| 2017-07-24 | Trevi Therapeutics, Inc. | Biotechnology | $61,906,460 | $51,906,460 | 18 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | TREVI THERAPEUTICS, INC. | CT | State business registries | name and state |
| Plan sponsor | TREVI THERAPEUTICS, INC. | CT | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Trevi Therapeutics, Inc. | CT | Form D private offerings | CIK (EXACT) |
| Patent assignee | Trevi Therapeutics, Inc. | CT | Patents (USPTO) | name and state |
| SEC filer | Trevi Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Trevi Therapeutics, Inc. | CT | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | TREVI THERAPEUTICS, INC. | EIN (EXACT) | ||
| Person page | Peter F Drake | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CT first:
- CHIREX INC CT
- ACHILLION PHARMACEUTICALS INC CT
- Rib-X Pharmaceuticals, Inc. CT
- Oracle Healthcare Acquisition Corp. CT
- NANOVIRICIDES, INC. CT
- KOLLTAN PHARMACEUTICALS INC CT
- Yarrow Bioscience, Inc. CT
- Loxo Oncology, Inc. CT
- ARVINAS, INC. CT
- Biohaven Pharmaceutical Holding Co Ltd. CT
In other datasets, the same topic (Health) in CT:
- Nonprofit: AIDS BUDDY NETWORK (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health